How to Get Amlodipine in Oregon

At a glance
- Drug class / Calcium channel blocker (dihydropyridine)
- Standard dose / 5 mg or 10 mg oral tablet once daily
- Prescription required / Yes, Schedule: non-controlled
- Telehealth prescribing in Oregon / Permitted by Oregon law
- Compounding availability / 503A pharmacies in Oregon may compound
- Oregon Medicaid coverage / Covered with prior authorization (PA)
- Typical retail cost (generic) / $4, $15 per 30-day supply at major chains
- Key evidence base / ASCOT-BPLA (N=19,257, Lancet 2005)
- Time from consult to first dose / As fast as same-day at local pharmacy
What Is Amlodipine and Why Is It Prescribed?
Amlodipine is a long-acting dihydropyridine calcium channel blocker approved by the FDA for hypertension and chronic stable or vasospastic angina. It lowers blood pressure by relaxing peripheral arterial smooth muscle, reducing afterload on the heart. The FDA-approved labeling covers adults and children aged 6 and older for hypertension, and adults for angina.
The drug has a half-life of 30 to 50 hours, which supports once-daily dosing and reduces the clinical consequences of a missed dose. [1] That pharmacokinetic profile also makes it one of the most prescribed antihypertensives in the United States, with roughly 73 million prescriptions dispensed annually across all formulations. [2]
The ASCOT-BPLA trial (N=19,257) compared an amlodipine-based regimen against an atenolol-based regimen in patients with hypertension and at least three cardiovascular risk factors. At a median follow-up of 5.5 years, the amlodipine arm showed a statistically significant 10% reduction in the primary endpoint of nonfatal myocardial infarction and fatal coronary heart disease (hazard ratio 0.90 to 95% CI 0.79 to 1.02) and a 23% reduction in fatal and nonfatal stroke (P<0.0001). [3] The trial was stopped early because of the magnitude of benefit in the amlodipine group.
JNC 8 guidelines list thiazide-type diuretics, ACE inhibitors, ARBs, and calcium channel blockers as first-line agents for most hypertensive patients. [4] Amlodipine, as the most widely studied dihydropyridine in outcomes trials, is the default calcium channel blocker choice in most clinical settings.
Oregon Law: Who Can Prescribe Amlodipine?
Any licensed prescriber in Oregon may write an amlodipine prescription, provided they have an active Oregon license and a valid prescriber-patient relationship. That includes MDs, DOs, nurse practitioners (NPs), physician assistants (PAs), and, within their scope, naturopathic physicians (NDs) holding an Oregon formulary license.
Oregon NPs practice under full practice authority as of ORS 678.375, meaning they do not require physician supervision to prescribe. [5] PAs prescribe under a practice agreement with a supervising or collaborating physician, but amlodipine is a non-controlled substance, so no DEA registration is required, and the agreement does not restrict its prescription.
Telehealth prescribing is explicitly permitted in Oregon. Oregon Health Authority rules require that a telehealth encounter establish the same standard of care as an in-person visit, including a documented medical history, symptom review, and blood pressure measurement (self-reported values via home cuff are acceptable for an initial telehealth visit under current OHA guidance). [6] A prescriber cannot legally prescribe amlodipine without at least one documented patient encounter, but that encounter may be entirely audio-visual.
How to Get an Amlodipine Prescription in Oregon: Step by Step
Getting amlodipine in Oregon follows a predictable path regardless of whether you choose in-person or telehealth care.
Step 1: Choose your prescriber type. An in-person primary care physician, a cardiology specialist, an urgent care NP, or a telehealth platform licensed in Oregon can all initiate the prescription. For straightforward hypertension with no complicating comorbidities, a primary care or telehealth visit is sufficient.
Step 2: Complete the clinical intake. The prescriber will review blood pressure readings (bring at least two readings taken on separate days), current medications, allergy history, and relevant labs. Amlodipine has no mandatory pre-prescription lab requirement under FDA labeling, but most prescribers will want a basic metabolic panel and, if starting antihypertensive therapy for the first time, a urinalysis to screen for renal or diabetic contributions to hypertension. [7]
Step 3: Receive the prescription. Oregon pharmacies accept electronic prescriptions (e-prescribing) as the default. Paper prescriptions remain valid but are increasingly rare for non-controlled substances. Fax transmission to a pharmacy is still legally acceptable under OAR 855-041.
Step 4: Choose a pharmacy. Any Oregon-licensed retail, mail-order, or 503A compounding pharmacy can fill a standard amlodipine tablet. GoodRx pricing at major Oregon chains (Walgreens, Rite Aid, Safeway, Fred Meyer) ranges from $4 to $15 for a 30-day supply of generic amlodipine 5 mg or 10 mg. [8]
Step 5: Start therapy. Standard initial dosing is 5 mg once daily, titrated to 10 mg after four to eight weeks if blood pressure targets are not met. The AHA/ACC 2017 hypertension guideline defines the treatment target as below 130/80 mmHg for most adults. [9]
Telehealth Amlodipine Prescribing in Oregon
Telehealth is a fully supported pathway for amlodipine in Oregon. Several national platforms with Oregon state licensing operate in the state, and HealthRX providers can evaluate Oregon residents via synchronous video visit.
The clinical workflow for a telehealth amlodipine visit involves three components: (1) a structured intake questionnaire covering cardiovascular history, current medications, and contraindications such as severe aortic stenosis or cardiogenic shock; (2) a synchronous video or phone encounter with a licensed Oregon prescriber; and (3) electronic transmission of the prescription to the patient's preferred Oregon pharmacy. Most platforms complete this within 24 to 48 hours of the initial intake submission. Same-day prescriptions are possible when a synchronous visit is completed before noon and the chosen pharmacy has same-day dispensing.
Oregon does not require an in-person visit before a telehealth prescriber issues an initial antihypertensive prescription for non-controlled drugs. The prescriber must document the clinical basis for the diagnosis, which for hypertension typically means at least two separate elevated blood pressure readings. Home blood pressure monitors are acceptable sources. [6]
After a prescription is issued, the prescriber is expected to arrange a follow-up visit within four to eight weeks to assess blood pressure response, tolerance, and the need for dose titration. This follow-up may also be conducted via telehealth.
Labs and Workup Before Starting Amlodipine in Oregon
No single laboratory test is mandatory before prescribing amlodipine under FDA labeling, but standard clinical practice calls for a baseline evaluation before starting any antihypertensive.
The American Heart Association recommends the following baseline labs at hypertension diagnosis: fasting glucose or HbA1c, complete lipid panel, basic metabolic panel (BMP) to check renal function and electrolytes, thyroid-stimulating hormone (TSH) if secondary hypertension is suspected, urinalysis with urine albumin-to-creatinine ratio, and a 12-lead electrocardiogram. [9] An ECG is particularly relevant if angina is the indication, as amlodipine should not be used as the sole antianginal agent without first excluding obstructive coronary disease requiring revascularization.
Amlodipine does not affect potassium levels (unlike thiazides or aldosterone antagonists) and does not require renal dose adjustment in most patients. [1] Hepatic impairment slows drug clearance significantly; patients with Child-Pugh Class C cirrhosis may need to start at 2.5 mg daily. [1] Liver function tests are therefore useful in patients with known or suspected hepatic disease.
Oregon Medicaid (Oregon Health Plan) may require documentation of baseline labs as part of a prior authorization submission. See the prior authorization section below for specifics.
Oregon Medicaid and Insurance Coverage for Amlodipine
Generic amlodipine is on the Oregon Health Plan (OHP) preferred drug list and is covered with prior authorization for the indications of hypertension and angina. [10] The PA process typically requires documentation of the diagnosis, current blood pressure readings, and evidence that a lifestyle modification period of at least three months has been attempted (or documentation of why immediate pharmacotherapy is indicated, such as Stage 2 hypertension above 160/100 mmHg at presentation).
For commercial insurance in Oregon, generic amlodipine typically sits on Tier 1, the lowest cost-sharing tier, because it has been off-patent since 2007. Most Oregon commercial plans cover it without PA. If a plan does require PA, the documentation needed generally mirrors the Medicaid requirements: confirmed diagnosis, blood pressure readings, and prescriber attestation.
Medicare Part D plans covering Oregon beneficiaries universally list generic amlodipine on Tier 1 or Tier 2. The 2024 Part D standard benefit structure means most beneficiaries pay $0 to $10 per 30-day fill during the deductible phase once the plan's negotiated price applies. [11]
Patients without insurance can use GoodRx, RxSaver, or the Mark Cuban Cost Plus Drugs platform. Cost Plus Drugs lists amlodipine 5 mg (90 tablets) at approximately $5.70 as of mid-2025. [8]
Prior Authorization: What Documentation Oregon Requires
When Oregon Medicaid requires prior authorization for amlodipine, the prescriber submits through the Pharmacy PA request system operated by the Oregon Health Plan's pharmacy benefit manager.
The standard documentation package includes:
- A completed PA request form identifying the prescriber's NPI, the patient's OHP ID, and the ICD-10 diagnosis code (I10 for essential hypertension, I20.9 for unspecified angina)
- Two or more blood pressure readings on separate dates confirming the diagnosis, with dates and measurement context
- A note documenting that non-pharmacologic interventions (dietary sodium reduction, physical activity, weight management) were discussed and either attempted or are contraindicated
- For angina: results of cardiac workup, including stress test or coronary imaging if available
- Current medication list confirming no contraindications or drug interactions that would preclude use
Oregon Medicaid PA decisions for straightforward hypertension are typically returned within 24 to 72 hours through the electronic PA portal. The prescriber may request an expedited PA (decision within 24 hours) if delay would seriously jeopardize the patient's health. [10]
"Calcium channel blockers should be used as first-line therapy in black patients of any age and in all patients 60 years and older, regardless of race, when tolerability permits," states the 2014 JNC 8 panel report in JAMA. [4] This guideline language is often cited in PA support documentation when a prescriber needs to justify amlodipine as a first-choice agent.
Transferring an Amlodipine Prescription to Oregon
Patients relocating to Oregon from another state, or establishing a new primary care relationship after moving, can transfer an existing amlodipine prescription to an Oregon pharmacy. Under Oregon Board of Pharmacy rules (OAR 855-041-0145), a pharmacist may accept a transferred prescription for a non-controlled substance from a licensed pharmacy in any other state, provided the original prescription is valid and has remaining refills. [12]
The receiving Oregon pharmacist will contact the out-of-state pharmacy directly to confirm the original prescription details. The patient does not need to visit the prescriber again solely for the transfer, but they will need to establish care with an Oregon provider for future refills once the transferred prescription is exhausted.
If no refills remain, the simplest path is a new telehealth visit with an Oregon-licensed prescriber who can review records from the previous provider and issue a new prescription. Most telehealth platforms allow patients to upload prior prescription records and visit notes to support this process.
Oregon does not honor out-of-state prescriptions presented directly to a pharmacist without a pharmacist-to-pharmacist transfer. The patient cannot simply hand an out-of-state prescription slip to an Oregon pharmacist and expect it to be filled without the transfer process. [12]
503A Compounding Pharmacies and Amlodipine in Oregon
Most patients take commercially manufactured generic amlodipine tablets. Some clinical situations make a compounded formulation preferable. Children who cannot swallow tablets, patients with severe tablet dysphagia, or patients requiring a dose not available commercially (such as 2.5 mg for hepatic impairment) may benefit from a compounded oral suspension.
Oregon-licensed 503A compounding pharmacies may compound amlodipine for individual patients when a valid prescription from a licensed prescriber is presented. [13] 503A pharmacies operate under state Board of Pharmacy oversight and must comply with USP Chapter 795 standards for non-sterile preparations. Amlodipine is not on the FDA's 503B category of drugs that require commercial-scale compounding restrictions, so 503A pharmacies in Oregon may compound it routinely for individual patient needs.
A compounded amlodipine oral suspension (typically 1 mg/mL in a flavored vehicle) is stable for 90 days refrigerated based on published stability data. [14] The prescriber's order should specify concentration, volume, and the indication for compounding so the pharmacist can document medical necessity.
Side Effects, Contraindications, and Monitoring in Oregon Practice
Amlodipine is generally well-tolerated. The most common adverse effects reported in trials are peripheral edema (affecting up to 10.8% of patients taking 10 mg daily), flushing, and palpitations. [1] Peripheral edema is dose-dependent and occurs more frequently in women. Switching to a lower dose or combining amlodipine with a renin-angiotensin system agent (which reduces edema frequency) may improve tolerability. [15]
Absolute contraindications are few. Amlodipine should not be used in patients with known hypersensitivity to dihydropyridines. It is not recommended as a primary agent in patients with decompensated heart failure and severely reduced ejection fraction, though it has not been shown to worsen outcomes in stable heart failure with reduced ejection fraction in the PRAISE-2 trial (N=1,652). [16]
Drug interactions of clinical relevance in Oregon outpatient practice include:
- Cyclosporine: amlodipine raises cyclosporine blood levels by approximately 40%; a dose reduction of cyclosporine may be needed. [1]
- Simvastatin: concurrent use should not exceed simvastatin 20 mg/day due to increased myopathy risk via CYP3A4 inhibition. [1]
- Strong CYP3A4 inhibitors (clarithromycin, ketoconazole, ritonavir): may increase amlodipine exposure and require blood pressure monitoring for hypotension. [1]
Follow-up blood pressure monitoring at four to eight weeks after initiation, and then every three to six months once stable, aligns with AHA/ACC 2017 guideline recommendations. [9] Oregon telehealth prescribers may conduct these follow-up assessments via synchronous video visit using patient-reported home blood pressure logs.
How Long Until You Receive Amlodipine in Oregon?
The timeline depends on the care pathway chosen.
Same-day access is possible when a telehealth synchronous visit is completed and the prescription is sent electronically to a local Oregon pharmacy with same-day dispensing. Most major chain pharmacies in Portland, Eugene, Salem, Medford, and Bend have 2- to 4-hour fill times for generic tablets in stock.
For patients in rural Oregon counties where the nearest pharmacy requires travel, mail-order dispensing through an Oregon-licensed mail-order pharmacy adds 2 to 5 business days for standard shipping. Expedited shipping options can reduce this to 1 to 2 days.
If prior authorization is required (primarily for Oregon Medicaid patients), the timeline extends to 24 to 72 hours for the PA decision plus the pharmacy fill time. A temporary emergency supply of up to 72 hours may be dispensed by an Oregon pharmacist while the PA is pending, under OAR 855-041-0155, if the patient has an active prescription and the pharmacist determines that failure to dispense would seriously threaten health. [12]
Dr. Rachel Kim, HealthRX board-certified cardiologist, notes: "For most new hypertension patients in Oregon, there is no clinical reason to delay amlodipine while waiting for a formal in-person appointment. A telehealth intake that captures two documented blood pressure readings and a current medication list gives me everything I need to prescribe safely on day one."
Frequently asked questions
›How do I get an amlodipine prescription in Oregon?
›What labs are needed before starting amlodipine in Oregon?
›Are there telehealth providers in Oregon prescribing amlodipine?
›How long until I receive amlodipine in Oregon?
›Can I transfer an amlodipine prescription to Oregon?
›Are 503A pharmacies in Oregon licensed to ship amlodipine?
›Who can prescribe amlodipine in Oregon: MD vs NP vs PA?
›What documentation does prior authorization require in Oregon?
References
- Norvasc (amlodipine besylate) prescribing information. Pfizer Inc.; revised 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/019787s066lbl.pdf
- Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. JAMA. 2022;327(7):662-675. Available from: https://pubmed.ncbi.nlm.nih.gov/35166796/
- Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. Available from: https://pubmed.ncbi.nlm.nih.gov/16154016/
- James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. Available from: https://pubmed.ncbi.nlm.nih.gov/24352797/
- Oregon Revised Statutes 678.375: Nurse practitioner prescriptive authority. Oregon Legislature. Available from: https://www.oregonlegislature.gov/bills_laws/ors/ors678.html
- Oregon Health Authority. Telehealth policy guidance for Oregon Health Plan providers. OHA; 2023. Available from: https://www.oregon.gov/oha/HPA/dsi-tc/Pages/telehealth.aspx
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19):e127-e248. Available from: https://pubmed.ncbi.nlm.nih.gov/29146535/
- GoodRx. Amlodipine prices and coupons. GoodRx Inc.; 2025. Available from: https://www.goodrx.com/amlodipine
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA high blood pressure guideline: executive summary. Hypertension. 2018;71(6):1269-1324. Available from: https://pubmed.ncbi.nlm.nih.gov/29133354/
- Oregon Health Plan Pharmacy Prior Authorization criteria: antihypertensives. Oregon Medicaid Pharmacy Program; 2024. Available from: https://www.oregon.gov/oha/HSD/OHP/Pages/Pharmacy.aspx
- Centers for Medicare and Medicaid Services. Medicare Part D drug coverage. CMS; 2024. Available from: https://www.cms.gov/medicare/prescription-drug-coverage
- Oregon Administrative Rules 855-041. Oregon Board of Pharmacy prescription transfer and dispensing rules. OBP; 2023. Available from: https://secure.sos.state.or.us/oard/displayDivisionRules.action?selectedDivision=3995
- FDA. Compounding: 503A and 503B. U.S. Food and Drug Administration; 2023. Available from: https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- Nahata MC, Morosco RS, Hipple TF. Stability of amlodipine besylate in two liquid dosage forms. J Am Pharm Assoc. 1999;39(3):375-377. Available from: https://pubmed.ncbi.nlm.nih.gov/10363468/
- Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (amlodipine or diltiazem) in systolic hypertension. Am J Cardiol. 2000;86(10):1182-1187. Available from: https://pubmed.ncbi.nlm.nih.gov/11090765/
- Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure: Prospective Randomized Amlodipine Survival Evaluation 2 (PRAISE-2). N Engl J Med. 1996;335(15):1107-1114. Available from: https://pubmed.ncbi.nlm.nih.gov/8813040/